Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 24650702)

1.

Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.

Yamakawa N, Suzuki K, Yamashita Y, Katsu T, Hanaya K, Shoji M, Sugai T, Mizushima T.

Bioorg Med Chem. 2014 Apr 15;22(8):2529-34. doi: 10.1016/j.bmc.2014.02.032. Epub 2014 Mar 12.

PMID:
24650702
2.

Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.

Ermondi G, Caron G, Lawrence R, Longo D.

J Comput Aided Mol Des. 2004 Nov;18(11):683-96.

PMID:
15865061
4.

COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.

Everts B, Währborg P, Hedner T.

Clin Rheumatol. 2000;19(5):331-43. Review.

PMID:
11055820
5.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.

6.
7.

Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.

Bhardwaj A, Kaur J, Wuest F, Knaus EE.

ChemMedChem. 2014 Jan;9(1):109-16, 240. doi: 10.1002/cmdc.201300355. Epub 2013 Oct 31.

PMID:
24376205
8.

Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.

Reddy RN, Mutyala R, Aparoy P, Reddanna P, Reddy MR.

Curr Pharm Des. 2007;13(34):3505-17. Review.

PMID:
18220787
9.

Synthesis and biological evaluation of loxoprofen derivatives.

Yamakawa N, Suemasu S, Matoyama M, Tanaka K, Katsu T, Miyata K, Okamoto Y, Otsuka M, Mizushima T.

Bioorg Med Chem. 2011 Jun 1;19(11):3299-311. doi: 10.1016/j.bmc.2011.04.050. Epub 2011 May 1.

PMID:
21570308
10.

Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.

Navidpour L, Amini M, Shafaroodi H, Abdi K, Ghahremani MH, Dehpour AR, Shafiee A.

Bioorg Med Chem Lett. 2006 Sep 1;16(17):4483-7. Epub 2006 Jun 27.

PMID:
16806914
11.

New celecoxib derivatives as anti-inflammatory agents.

Szabó G, Fischer J, Kis-Varga A, Gyires K.

J Med Chem. 2008 Jan 10;51(1):142-7. Epub 2007 Dec 12.

PMID:
18072726
12.

Tracing the origins of COX-2 inhibitors' structures.

Lednicer D.

Curr Med Chem. 2002 Aug;9(15):1457-61. Review.

PMID:
12173976
13.

[Coxibs: cyclooxygenase-2 inhibitors].

Turnheim K.

Wien Klin Wochenschr. 2001 Aug 16;113(15-16):558-65. Review. German.

PMID:
11571832
14.

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.

Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ; Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group.

JAMA. 2002 Jan 2;287(1):64-71. Erratum in: JAMA 2002 Feb 27;287(8):989.

PMID:
11754710
15.

Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.

Phelan KM, Mosholder AD, Lu S.

J Clin Psychiatry. 2003 Nov;64(11):1328-34. Review.

PMID:
14658947
17.

Synthesis of N-benzenesulfonamide-1H-pyrazoles bearing arylsulfonyl moiety: novel celecoxib analogs as potent anti-inflammatory agents.

Abdel-Aziz HA, Al-Rashood KA, ElTahir KE, Suddek GM.

Eur J Med Chem. 2014 Jun 10;80:416-22. doi: 10.1016/j.ejmech.2014.04.065. Epub 2014 Apr 24.

PMID:
24794773
18.

Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.

Quiralte J, Delgado J, Sáenz de San Pedro B, López-Pascual E, Nieto MA, Ortega N, Florido JF, Conde J.

Ann Allergy Asthma Immunol. 2004 Oct;93(4):360-4.

PMID:
15521372
19.

Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury.

Tanaka A, Araki H, Hase S, Komoike Y, Takeuchi K.

Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:90-101.

PMID:
11966529
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk